Bristol-Myers Squibb (NYSE: BMY), often referred to as BMS, is a pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York (both were graduates of Hamilton College).
Campaign Finance$14,548,954 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Bristol-Myers Squibb
Names of Lobbyists
Firm Hired Amount Bristol-Myers Squibb $64,035,355
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Consumer Product Safety,
- Clean Air & Water
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1260 Patent Reform Act of 2009 S.515 Patent Reform Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.4872 Health Care and Education Affordability Reconciliation Act of 2010 H.R.3962 Affordable Health Care for America Act H.R.4213 Tax Extenders Act of 2009 S.565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009 H.R.1548 Pathway for Biosimilars Act S.1679 Affordable Health Choices Act
RegulationsMentioned in 637 dockets; Submitted to 57 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Bristol-Myers Squibb" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Bristol-Myers Squibb
- Toggle 3 FDA Harmonize the agency's acceptable document delivery methods. 1997
- Toggle 2 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 2 FDA Draft Guidance for Industry on Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications; Availability 2009
- Toggle 2 FDA Over-the-Counter Drug Products;Public Hearing 2000
- Toggle 2 FDA Electronic Signatures: Time Stamps 2000
- Toggle 2 FDA Electronic Records & Signatures, Retention of Electronic Rec 2000
- Toggle 2 FDA Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that are Regulated Under a Biologics License Application, and Animal Drugs 2005
- Toggle 1 USTR Request for Comments Concerning Free Trade Agreement With the Republic of Korea 2009
- Toggle 1 DOT 2005/2006 U.S.-China Air Services Case and Designations 2004
- Toggle 1 FDA Report to Congress on Pediatric Exclusivity 2000
Mentions in Document Text
View all mentions data for Bristol-Myers Squibb
- Toggle 28 EPA Standards of Performance for New Stationary Sources and Emission Guidelines for Existing Sources: Hospital/Medical/Infectious Waste Incinerators 2006
- Toggle 20 FDA Generic Drug Speeches & Policy and Procedure Guides 1990
- Toggle 10 FDA Patent Extension Application for SPRYCEL (dasatinib), U.S. Patent No. 6,596,746 2006
- Toggle 9 FDA Refrain From or Approving any Application for a 0.6 mg Oral Colchicine Tablet with a Proposed Indication Already Approve for Colcrys® That is not Submitted as an Appreviated New Drug Application - CLOSED 2010
- Toggle 9 FDA Patent Extension Application for ORENCIA (abatacept), U.S. Patent No. 5,851,795 2006
- Toggle 9 FDA Applications for FDA Approval to Market a New Drug 2002
- Toggle 8 FDA Patent Term Extension Application for IXEMPRA (ixabepilone), U.S. Patent No. 6,605,599 2008
- Toggle 8 EPA Human Studies Review Board Meeting 2007
- Toggle 7 FDA Take Special Consideration When Reviewing any Abbreviated new Drug Application (ANDA) for a Generic Version of Cardiolite 2008
- Toggle 7 FDA Patent Extension for ONGLOYZA, U.S. Patent No. 6,395,767 2010
EPA Violations8 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Bristol-Myers Squibb Company (National Case)||Bristol-Myers Squibb||2009||Barceloneta, Pr; Buffalo, ...||$3,582,262|
|Alliance Chemical Inc Et Al.||Bristol-Myers Squibb Company (+71 others)||2007||Newark, Nj||$37,000,000|
|3m Company||Bristol-Myers Squibb Company (+106 others)||2008||Wood Ridge, Nj||$18,000,000|
|American Locker Group Inc.||Bristol-Meyers Squibb Company Inc (+5 others)||2009||Lincklaen, Ny||$14,821,000|
|Agere Systems, Et Al||Bristol Myers Company (+138 others)||2007||Elkton, Md||$11,300,000|
|3m Company Et Al.||Bristol-Myers Squibb Company (+67 others)||2004||Carlstadt, Nj||$8,649,902|
|American Standard, Inc. Et Al.||Bristol-Myers Squibb Company (+6 others)||2010||South Brunswick, Nj||$4,560,000|
|Abb, Inc.||Bristol-Myers Squibb Company (+72 others)||2007||Wood Ridge, Nj||$1,400,000|
Advisory Committees15 people on 14 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Bristol-Myers Squibb" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 9 people on 8 committees
- Toggle Department of State 2 people on 1 committee
- Toggle National Science Foundation 1 person on 2 committees
- Toggle Department of Commerce 1 person on 1 committee
- Toggle Environmental Protection Agency 1 person on 1 committee
- Toggle Department of the Treasury 1 person on 1 committee